Vivos Inc. Announces IDE Submission for RadioGel™
Vivos Inc. (RDGL) announces submission of IDE application to FDA for RadioGel™, advancing treatment for papillary thyroid cancer.
Copy and paste this URL into your WordPress site to embed
Copy and paste this code into your site to embed
